celastrol has been researched along with tanespimycin in 2 studies
| Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) | Studies (tanespimycin) | Trials (tanespimycin) | Recent Studies (post-2010) (tanespimycin) |
|---|---|---|---|---|---|
| 885 | 1 | 741 | 921 | 39 | 496 |
| Protein | Taxonomy | celastrol (IC50) | tanespimycin (IC50) |
|---|---|---|---|
| Corticotropin releasing hormone receptor 2 | Sus scrofa (pig) | 0.004 | |
| Lysine-specific demethylase 6B | Homo sapiens (human) | 0.4 | |
| Lysine-specific demethylase 4B | Homo sapiens (human) | 0.7 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 3 | |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | 7.65 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.031 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.9391 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.5124 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 3 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 0.13 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.031 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 1.496 | |
| Putative heat shock protein HSP 90-alpha A4 | Homo sapiens (human) | 0.78 | |
| Lysine-specific demethylase 4C | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dannenberg, AJ; Guttenplan, JB; Hughes, D; Marcus, CB; Subbaramaiah, K | 1 |
| Boridy, S; Le, PU; Maysinger, D; Petrecca, K | 1 |
2 other study(ies) available for celastrol and tanespimycin
| Article | Year |
|---|---|
Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Benzoquinones; Carcinoma, Squamous Cell; Cells, Cultured; Chemoprevention; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; DNA Adducts; Drug Evaluation, Preclinical; Enzyme Activation; Gene Expression Regulation, Enzymologic; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Models, Biological; Pentacyclic Triterpenes; Precancerous Conditions; Receptors, Aryl Hydrocarbon; Transcription, Genetic; Triterpenes | 2008 |
Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzoquinones; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Glioblastoma; Homeostasis; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lysosomes; Pentacyclic Triterpenes; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Signal Transduction; Sulfhydryl Compounds; Triterpenes; Tumor Cells, Cultured; Ubiquitination | 2014 |